Home › 2026-18133
Advancing Development of Botanical Drug Products; Request for Information
Read on FederalRegister.gov · Official PDF · Docket on Regulations.gov · Submit a comment · Add to calendar (.ics)
Summary (from the Federal Register abstract)
The Food and Drug Administration (FDA or Agency) is opening a public docket to solicit comments on FDA's efforts to advance development of botanical drug products (BDPs). FDA is publishing this request for information to better understand stakeholders' perspectives on the state of BDP development in the United States, challenges encountered, and potential solutions to gathering the information required by the Federal Food, Drug, and Cosmetic Act (FD&C Act).
- Document type
- Notice
- Federal Register document number
- 2026-18133
- Published
- Sep 4, 2026
- Action
- Notice; request for information; establishment of a public docket.
- Docket
- FDA-2026-N-9550
- Comments posted on Regulations.gov (at last check)
- 37
- DATES section (from the document)
- Submit either electronic or written comments, data, or information by November 3, 2026.
- Topics (auto-tagged)
- Other FDA topics
Source: Federal Register API, document 2026-18133. Federal Register text is a U.S. government work. Confirm dates in the official document; later documents may extend, reopen or correct them.